Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Mindset Pharma Inc.
  6. News
  7. Summary
    MSET   CA60268M1023

MINDSET PHARMA INC.

(MSET)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the COPE Program with InterVivo Solutions

10/14/2021 | 07:30am EST

Mindset Pharma Inc. announced that, under its Co-operative Psychedelics Evaluation Platform program with InterVivo Solutions (“InterVivo”), the Company has further developed its first generation psychedelics benchmarking data by establishing standard pharmacokinetic, brain penetration, and drug discrimination data and protocols across LSD, psilocybin, and 5-MeO-DMT. The COPE Program is a translational testing platform developed in cooperation with InterVivo to introduce an industry standard against which the performance and efficacy of breakthrough psychedelic medicines are compared and assessed. Through this platform, Mindset and InterVivo intend to establish the first comprehensive psychedelics benchmark reference data set by evaluating a broad range of psychedelic drugs through a proprietary program of in vivo tests conducted at InterVivo's facility. The COPE program is anticipated to represent an invaluable tool to guide the development of next-generation psychedelic compounds and improve patentability and value in new molecule drug assets.


ę S&P Capital IQ 2021
All news about MINDSET PHARMA INC.
11/08Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-..
GL
10/26Mindset Pharma Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
AQ
10/26Mindset Pharma Inc Reports Earnings Results for the Fiscal Year Ended June 30, 2021
CI
10/26MINDSET PHARMA TO PARTICIPATE IN WON : Miami on November 8-9, 2021
GL
10/18KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Vie..
AQ
10/14MINDSET PHARMA : Expands Benchmarking Data for First Generation Psychedelics Through the C..
AQ
10/14Mindset Pharma Expands Benchmarking Data for First Generation Psychedelics Through the ..
CI
10/11KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
AQ
09/29MINDSET PHARMA EXPANDS PIPELINE : Identifies Additional Next Generation 5-MeO-DMT-Inspired..
GL
09/29Mindset Pharma Expands Pipeline Identifies Additional Next Generation 5-MeO-DMT-Inspire..
CI
More news
Financials
Sales 2022 - - -
Net income 2022 -15,6 M -12,2 M -12,2 M
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 62,4 M 48,8 M 48,7 M
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees -
Free-Float -
Chart MINDSET PHARMA INC.
Duration : Period :
Mindset Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
James Andre Charles Lanthier Chief Executive Officer
Arvin Ramos Chief Financial Officer
Richard J. Patricio Chairman
Joseph Araujo Director & Chief Science Officer
James Christopher Passin Director
Sector and Competitors
1st jan.Capi. (M$)
MINDSET PHARMA INC.-24.47%49
MODERNA, INC.161.69%110 846
LONZA GROUP AG25.95%56 890
IQVIA HOLDINGS INC.48.11%50 694
SEAGEN INC.-1.11%31 671
CELLTRION, INC.-40.39%23 975